Last $52.52 USD
Change Today +0.42 / 0.81%
Volume 1.5M
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVA) Snapshot

Open
$52.40
Previous Close
$52.10
Day High
$52.54
Day Low
$52.00
52 Week High
07/24/14 - $55.70
52 Week Low
11/5/13 - $36.26
Market Cap
44.9B
Average Volume 10 Days
2.4M
EPS TTM
--
Shares Outstanding
854.0M
EX-Date
08/19/14
P/E TM
--
Dividend
$1.37
Dividend Yield
2.60%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVA)

teva pharmaceutical-sp adr (TEVA) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical-sp adr (TEVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVA) Key Developments

Venus Remedies Partners Teva to Sell Anti-Cancer Drug

Venus Remedies announced that it has signed a collaborative agreement with Teva for selling an anti-cancer drug in the Canadian market to enhance business. Initially, Venus will manufacture the drug in its research unit called Venus Medicine Research Centre and assisting Teva in registrations.

Teva Pharmaceutical Industries Initiates Laquinimod Clinical Trial in Huntington's Disease

Active Biotech announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington's disease.

Teva Pharmaceutical Industries Limited Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of Fiscal 2014

Teva Pharmaceutical Industries Limited announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced net revenues of $5,045 million compared to $4,924 million for the same period a year ago. Operating income was $925 million compared to operating loss of $586 million for the same period a year ago. Income before income taxes was $847 million compared to loss before income taxes of $675 million for the same period a year ago. Net income was $745 million compared to net loss of $456 million for the same period a year ago. Net income attributable to the company was $748 million or $0.87 per diluted share compared to net loss attributable to the company of $452 million or $0.53 per diluted share for the same period a year ago. Non-GAAP net income attributable to the company was $1,054 million compared to $1,018 million for the same period a year ago. Non-GAAP earnings per share attributable to the company, diluted were $1.23 compared to $1.20 for the same period a year ago. Net cash provided by operating activities was $1,053 million compared to $875 million for the same period a year ago. Free cash flow, excluding net capital expenditures and dividends amounted to $583 million, an increase of $205 million from the second quarter of 2013. For the six months, the company announced net revenues of $10,046 million compared to $9,825 million for the same period a year ago. Operating income was $1,897 million compared to $288 million for the same period a year ago. Income before income taxes was $1,738 million compared to $24 million for the same period a year ago. Net income was $1,485 million compared to $170 million for the same period a year ago. Net income attributable to the company was $1,492 million or $1.75 per diluted share compared to $178 million or $0.21 per diluted share for the same period a year ago. Non-GAAP net income attributable to the company was $2,092 million compared to $1,978 million for the same period a year ago. Non-GAAP earnings per share attributable to the company, diluted were $2.45 compared to $2.32 for the same period a year ago. Net cash provided by operating activities was $1,951 million compared to $1,977 million for the same period a year ago. The company provided earnings guidance for the full year of fiscal 2014. The company announced that EPS guidance improved to $4.90 to $5.10 and revenue in the range of $19.8 billion to $20.8 billion, exclusive Copaxone scenario and to $4.50 to $4.80 in the generic Copaxone scenario.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $52.52 USD +0.42

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.24 USD -0.11
AbbVie Inc $55.28 USD -0.32
Baxter International Inc $74.98 USD +0.07
Eli Lilly & Co $63.56 USD +0.45
Johnson Matthey PLC 3,171 GBp +13.00
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 17.3x
Price/Sales 2.2x
Price/Book 1.9x
Price/Cash Flow 19.4x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.